Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (daunorubicin + cytarabine liposome)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351, marketed under the brand name Vyxeos, is a liposomal formulation containing a fixed 5:1 molar ratio of the antineoplastic agents cytarabine and daunorubicin. This specific ratio was identified through in vitro screening to maximize synergistic antileukemic activity while minimizing antagonistic effects. The liposomal delivery system extends the plasma half-life of both drugs and facilitates their preferential accumulation and uptake within the bone marrow, where they are released to target leukemic blasts. CPX-351 is primarily indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It was originally developed by Celator Pharmaceuticals, which was subsequently acquired by Jazz Pharmaceuticals.
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicindaunorubicin and cytarabine liposome
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CPX-351 (daunorubicin + cytarabine liposome).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (daunorubicin + cytarabine liposome).